Carbon dioxide and MAPK signalling: towards therapy for inflammation
Hanna Gałgańska, Wiesława Jarmuszkiewicz, Łukasz Gałgański
Abstract
Abstract Inflammation, although necessary to fight infections, becomes a threat when it exceeds the capability of the immune system to control it. In addition, inflammation is a cause and/or symptom of many different disorders, including metabolic, neurodegenerative, autoimmune and cardiovascular diseases. Comorbidities and advanced age are typical predictors of more severe cases of seasonal viral infection, with COVID-19 a clear example. The primary importance of mitogen-activated protein kinases (MAPKs) in the course of COVID-19 is evident in the mechanisms by which cells are infected with SARS-CoV-2; the cytokine storm that profoundly worsens a patient’s condition; the pathogenesis of diseases, such as diabetes, obesity, and hypertension, that contribute to a worsened prognosis; and post-COVID-19 complications, such as brain fog and thrombosis. An increasing number of reports have revealed that MAPKs are regulated by carbon dioxide (CO 2 ); hence, we reviewed the literature to identify associations between CO 2 and MAPKs and possible therapeutic benefits resulting from the elevation of CO 2 levels. CO 2 regulates key processes leading to and resulting from inflammation, and the therapeutic effects of CO 2 (or bicarbonate, HCO 3 − ) have been documented in all of the abovementioned comorbidities and complications of COVID-19 in which MAPKs play roles. The overlapping MAPK and CO 2 signalling pathways in the contexts of allergy, apoptosis and cell survival, pulmonary oedema (alveolar fluid resorption), and mechanical ventilation–induced responses in lungs and related to mitochondria are also discussed.